![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
MF O'Rourke, HS Blaxall, LJ Iversen and DB Bylund
Department of Pharmacology, University of Nebraska Medical Center, Omaha.
Alpha-2 adrenergic receptors have been divided into four pharmacological subtypes based on their differences in affinity for several drugs. Previous studies showed that [3H]RX821002 has a high affinity for the alpha-2A subtype. The current study characterized the binding properties of [3H]RX821002 [2-(2-methoxy-1,4- benzodioxan-2yl)- 2-imidazoline] to the alpha-2A receptor in CHO-C10 cells, alpha-2B in neonatal rat lung, alpha-2C in OK cells and alpha-2D in bovine pineal gland. Membrane binding studies of [3H]RX821002 were done in 25 mM glycylglycine buffer at room temperature. The nonspecific binding rates at the KD concentration were 4.9%, 20%, 14% and 8.3% of the total for CHO-C10, neonatal rat lung, OK cells and bovine pineal, respectively, which were determined by adding 100 microM norepinephrine. Saturation curves indicate that [3H]RX821002 has a high affinity for all alpha-2 adrenergic subtypes. The KD values were 0.29, 1.05, 0.37 and 0.19 nM for CHO-C10, neonatal rat lung, OK cells and bovine pineal, respectively. [3H]Rauwolscine has affinities of 0.34, 0.55 and 0.24 nM for the alpha-2A, -2B and -2C subtypes. By contrast, [3H]rauwolscine has a much lower affinity for alpha-2D subtype with a KD value of 5.2 nM. The binding site density for [3H]RX821002 was significantly lower in the neonatal rat lung compared with [3H]rauwolscine. The correlation coefficients of pKi values of adrenergic compounds against [3H]RX821002 versus [3H]rauwolscine were close to unity for each tissue. These data clearly show that the two ligands label the same alpha-2 adrenergic receptor population.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  D. P. Naselsky, D. Ashton, R. R. Ruffolo Jr., and J. P. Hieble Rabbit alpha 2-Adrenoceptors: Both Platelets and Adipocytes Have alpha 2A-Pharmacology J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 219 - 225. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Hayar and P. G. Guyenet alpha 2-Adrenoceptor-mediated presynaptic inhibition in bulbospinal neurons of rostral ventrolateral medulla Am J Physiol Heart Circ Physiol, September 1, 1999; 277(3): H1069 - H1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Aicher and C. T. Drake Clonidine Evokes Vasodepressor Responses via alpha 2-Adrenergic Receptors in Gigantocellular Reticular Formation J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 688 - 694. [Abstract] [Full Text]
|
|
|
|
|
|
H. K. Happe, D. B. Bylund, and L. C. Murrin Alpha-2 Adrenergic Receptor Functional Coupling to G Proteins in Rat Brain During Postnatal Development J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1134 - 1142. [Abstract] [Full Text]
|
|
|
|
|
|
D. Huangfu and P. G. Guyenet alpha 2-Adrenergic autoreceptors in A5 and A6 neurons of neonate rats Am J Physiol Heart Circ Physiol, November 1, 1997; 273(5): H2290 - H2295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Bylund, L. J. Iversen, W. J. Matulka, and D. M. Chacko J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1171 - 1177. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
